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Abstract 
Introduction: Dientamoeba fragilis, an intestinal trichomonad, occurs in humans with and without gastrointestinal symptoms. Its presence was 
investigated in individuals referred to Milad Hospital, Tehran. 
Methodology: In a cross-sectional study, three time-separated fecal samples were collected from 200 participants from March through June 
2011. Specimens were examined using traditional techniques for detecting D. fragilis and other gastrointestinal parasites: direct smear, culture, 
formalin-ether concentration, and iron-hematoxylin staining. The presence of D. fragilis was determined using PCR assays targeting 5.8S 
rRNA or small subunit ribosomal RNA. 
Results: Dientamoeba fragilis, Blastocystis sp., Giardia lamblia, Entamoeba coli, and Iodamoeba butschlii were detected by one or more 
traditional and molecular methods, with an overall prevalence of 56.5%. Dientamoeba was not detected by direct smear or formalin-ether 
concentration but was identified in 1% and 5% of cases by culture and iron-hematoxylin staining, respectively. PCR amplification of SSU 
rRNA and 5.8S rRNA genes diagnosed D. fragilis in 6% and 13.5%, respectively. Prevalence of D. fragilis was unrelated to participant gender, 
age, or gastrointestinal symptoms. 
Conclusions: This is the first report of molecular assays to screen for D. fragilis in Iran. The frequent finding of D. fragilis via fecal analysis 
indicated the need to include this parasite in routine stool examination in diagnostic laboratories. As the length of amplification target correlates 
to the sensitivity of PCR, this assay targeting the D. fragilis 5.8S rRNA gene seems optimal for parasite detection and is recommended in 
combination with conventional microscopy for diagnosing intestinal parasites.  
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Introduction 
Dientamoeba fragilis Jepps and Dobell 1918 
(Monocercomonadidae, Sarcomastigophora) is a 
trichomonad parasite infecting the gastrointestinal tract 
of humans and other vertebrates, including sheep, pigs, 
and birds [1,2]. This microorganism shows extensive 
genetic diversity, comprising variants morphologically 
related but distinct in their pathogenicity [3-5]. 
Although described about century ago, D. fragilis 
biology, virulence, pathogenicity, epidemiology, and 
mode of transmission are not well understood, and 
findings can be conflicting [4,6,7].  
Dientamoeba fragilis infections range from 
asymptomatic to causing acute or chronic disease in 
children and adults. The most common symptom of 
dientamoebiasis is diarrhea, followed by abdominal 
pain, fatigue, anorexia, and flatulence [8-10]. 
Dientamoebiasis may occur at any age and has a 
cosmopolitan distribution. Prevalence of D. fragilis 
infection varies considerably and is influenced by 
factors including geographic location, population 
density, living conditions, and level of hygiene and 
sanitation [1]. Data on the international prevalence of 
D. fragilis are limited. Worldwide, the prevalence has 
been reported to range from 0.4% to 71% [2,8,11,12], 
making it a more frequent cause of gastrointestinal 
infection than Giardia lamblia [13-15]. The sensitivity 
of diagnostic techniques and the expertise of testing 
laboratories affect the reported prevalence rate of D. 
fragilis [14,16]. Common methods such as direct smear 
and culture are challenging and require experience to 
distinguish D. fragilis from other gastrointestinal 
parasites [17]. Accurate identification depends on 
detection of the trophozoites in permanently stained 
stool smears, since the nuclear structure cannot be 
demonstrated in unstained stool samples [18]. The 
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staining technique is generally laborious, time 
consuming, and relatively insensitive. The development 
of PCR has provided a highly sensitive and specific 
method for diagnosis of pathogenic protozoa. PCR-
based assays using species-specific primers offer a 
convenient and reliable technique for the detection of 
D. fragilis [17,19]. 
Intestinal parasitic infections are a critical public 
health problem in Iran; however, research on D. fragilis 
has been limited. Its reported prevalence, as determined 
by the direct smear method, varies from 0.5 to 2.4% 
depending on area of the country [20-22]. Using the 
iron-hematoxylin staining method, Jamali and 
Khademvatan [23] reported prevalence of 13.2%. As D. 
fragilis is a signiﬁcant human pathogen, further 
research on its occurrence and effects is warranted 
[2,24]. We therefore aimed to investigate D. fragilis 
infection in individuals referred to Milad Hospital in 
Tehran, comparing traditional and molecular methods 
of detection. 
 
Methodology 
Sample collection 
In a cross-sectional study, three fresh fecal 
specimens, separated by at least one day, were collected 
from each of the 200 participants referred to the clinical 
laboratory of Milad Hospital in Tehran, from March 
through July 2011. Participants provided informed 
consent and the study was approved by Ethics 
Committee under number IR.IUMS.FMD.REC 
1390.1065. Fecal specimens were immediately 
submitted to the research laboratory of the Department 
of Parasitology and Mycology, School of Medicine, 
Iran University of Medical Sciences. All specimens 
were investigated for parasites by direct wet-mount 
microscopy, formalin-ether concentration, culture, 
modified iron-hematoxylin staining, and two PCR 
assays for D. fragilis. 
 
Microscopic examination 
Direct wet-mount microscopy and formalin-ether 
concentration methods 
Stool specimens were investigated microscopically 
for trophozoites forms of intestinal protozoan parasites 
using direct wet-mount in saline and iodine-solution 
(Lugol's iodine) [10]. Formalin-ether concentration was 
conducted to identify ova and cysts or oocysts [25,26]. 
 
Sample preparation and culture 
To a 10-20 g fecal sample, 50 mL of phosphate 
buffered saline (PBS) pH 7.4 was added and thoroughly 
mixed. The suspension was filtered through two layers 
of gauze and centrifuged at 800 × g for 5 min. 
Sediments were re-suspended in ~2 mL of PBS before 
combining with culture medium and fixing in either 
sodium acetate-acetic acid-formalin (SAF) or 80% 
ethanol [27-29]. 
For isolation of intestinal protozoa to be cultivated 
in an axenic medium, feces were cultured in a diphasic 
medium as described by Clark and Diamond [30]: slope 
of heat-inactivated horse serum (kindly provided by the 
Faculty of Veterinary Medicine, University of Tehran, 
Iran) overlaid with 5 mL of Ringer’s solution and 
supplemented with ~1 mg rice starch (HSr+S). 
Penicillin-streptomycin (Sigma–Aldrich, Steinheim, 
Germany) was added to control the growth of human 
bacterial ﬂora. A 300 µL sample of washed and 
unpreserved stool were added to culture tubes 
containing medium and rice starch and incubated in a 
vertical position at 35.5 °C. A drop of sediment from 
the tube was examined on a microscope slide three 
times at 48 hours intervals at 100× and 400× 
magnification. 
 
Staining 
The stool samples fixed in SAF were stained with 
modified iron-hematoxylin stain according to methods 
for identification of protozoa [9,27,31]. Precise 
microscopic diagnosis of D. fragilis was based on 
morphological characters from permanent stained 
smears at 400× and 1000× magnification. All slides 
were examined by two independent examiners. 
 
Molecular examination 
DNA extraction 
One mL of stool preserved in 80% ethanol was 
centrifuged at 1000 × g for 5 minutes, and the sediment 
was re-suspended in PBS and washed twice in sterile 
PBS to remove ethanol. After washing, the sediment 
was re-suspended in 200 µL 2% 
polyvinylpolypyrrolidone (PVPP) (Sigma–Aldrich, 
Steinheim, Germany) in PBS, combined thoroughly, 
and stored at -20 °C for 24 hours [28]. The samples 
were heated for 10 minutes at 100 °C before submitting 
to DNA extraction using the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions, modified according to 
Verweij et al. [28]. 
 
Polymerase chain reactions 
Conventional PCR was performed on samples to 
amplify a D. fragilis 98 bp 5.8S rDNA product [28] and 
an 887 bp SSU rDNA fragment as previously described 
[27]. To target 5.8S rRNA, the primers DF-124 (5’-
Hamidi et al. – Dientamoeba fragilis diagnosis by fecal screening     J Infect Dev Ctries 2018; 12(1):052-059. 
54 
CAACGGATGTCTTGGCTCTTTA-3’) and DF-221 
(5’-TGCATTCAAAGATCGAACTTATCAC-3’) [28] 
were used in 15 µL of an amplification reaction mixture 
with 7.5 µL Taq DNA polymerase 2X-preMix 
(GeneOn, Germany), 2 µL of genomic DNA, and 0.4 
µM of each primer. Reaction conditions were 3 minutes 
at 95 ºC followed by 50 cycles of 95 ºC for 15 s and 60 
ºC for 60 s, with a final extension of 72 ºC for 2 
minutes. Amplification products were separated on 
2.5% (W/V) agarose gel by electrophoresis.  
The primers DF400 (5’-
TATCGGAGGTGGTAATGACC-3’) and DF1250 
(5’-CATCTTCCTCCTGCTTAGACG-3’) targeting 
SSU (18S) rRNA [27] in 20 µL final PCR reaction [10 
µL of Taq DNA polymerase 2X-preMix (GeneOn, 
Ludwigshafen, Germany), 2 µL genomic DNA, and 0.4 
µM of each PCR primer] with the reaction conditions 
of 3 minutes at 94 ºC followed by 30 cycles of 94 ºC 
for 1 minutes, 57 ºC for 1.5 minutes, and 72 ºC for 2 
minutes and a final step of 7 minutes at 72 ºC. The PCR 
products were detected on ethidium bromide stained 
1.5% agarose gels. All PCR reactions included a 
negative control containing sterile distilled water 
instead of DNA template and a positive control 
containing genomic DNA extracted from a stool 
specimen microscopically conﬁrmed to be infected with 
D. fragilis. Some D. fragilis PCR-positive samples 
were confirmed by sequencing an 887 bp amplified 
SSU rRNA gene fragment in both directions (MWG-
Biotech Company, Ebersberg, Germany). The sequence 
results were read by CHROMAS (Technelysium Pty 
Ltd., Queensland, Australia) and aligned using 
DNASIS MAX v. 3.0 (Hitachi, Yokohama, Japan). The 
final SSU rDNA sequencing results were compared 
with the Genbank database using the BLASTN program 
(http://www.ncbi.nlm.nih.gov/BLAST/). Phylogenetic 
analysis was performed in MEGA7 
(www.megasoftware.net) using the neighbor-joining 
method, and the evolutionary distances were computed 
using the Kimura 2-parameter method and a bootstrap 
value of 1000.  
 
Statistical analysis 
Statistical analysis was performed using SPSS 16.0 
software (SPSS Inc., Chicago, USA). A descriptive 
analysis was conducted to determine the prevalence of 
parasites by gender, age group, clinical symptoms, and 
reason for referral. Associations between qualitative 
variables were evaluated using the chi-square (χ2) test 
to reveal statistically significant values (p-value < 
0.05). 
 
Results 
Participant enrollment 
Two-hundred participants were enrolled in the 
study, 50.5% female and 49.5% male. The mean age 
was 27.6 ± 19.1 years, ranging from one to 79 years. 
Most participants lived in Tehran Province (86%), with 
Table 1. Characteristics and clinical features of participants positive and negative for D. fragilis 
 Participants 
 Positive n = 27 Negative n =173 Total n =200 p-value 
Age years (Mean ± SD) 31.7 ± 19.8 26.9 ± 19.0 27.6 ± 19.1 0.23 
Gender     
Male (%) 13 (6.5) 86 (43.0) 99 (49.5) 
0.88 
Female (%) 14 (7.0) 87 (43.5) 101 (50.5) 
Clinical symptoms     
Diarrhea (%) 5 (18.5) 26 (15.0) 31 (15.5) 0.21 
Anorexia (%) 2 (7.4) 12 (6.9) 14 (7.0) 0.93 
Abdominal pain (%) 8 (29.6) 54 (31.2) 62 (31.0) 0.87 
Flatulence (%) 4 (14.8) 27 (15.6) 31 (15.5) 0.92 
Cramping (%) 8 (29.6) 38 (22.0) 46 (23.0) 0.92 
Nausea (%) 4 (14.8) 11 (6.4) 15 (7.5) 0.42 
Vomiting (%) 1 (3.7) 5 (2.9) 6 (3.0) 0.82 
Urticaria (%) 2 (7.4) 6 (3.5) 8 (4.0) 0.33 
Constipation (%) 0 (0.0) 4 (2.3) 4 (2.0) 0.43 
Reason for referral     
Routine exam (%) 14 (12.2) 101 (87.8) 115 (57.5) 
0.43 Gastrointestinal disorder (%) 12 (16.0) 63 (84) 75 (37.5) 
Non-gastrointestinal disorder (%) 1 (10.0) 9 (90) 10 (5.0) 
Participant home     
Tehran province (%) 23 (13.4) 149 (86.6) 172 (86.0) 
0.54 
Other province (%) 4 (14.3) 24 (85.7) 28 (14.0) 
Clinical symptom percentages do not total 100% as some participants had multiple symptoms. 
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14% referred from other provinces. Participants were 
categorized according the reason for referral: routine 
medical examination (115), gastrointestinal symptoms 
(75), or non-gastrointestinal disorders (10). 
Gastrointestinal symptoms were diarrhea (41.3%, 
31/75), anorexia (18.7%, 14/75), abdominal pain 
(82.7%, 62/75), flatulence (41.3%, 31/75), cramping 
(61.3%, 46/75), nausea (20%, 15/75), vomiting (8%, 
6/75), and constipation (5.3%, 4/75) (Table 1). 
 
Microscopic analysis 
Examination by direct microscopy, formalin-ether 
concentration, and culture and staining techniques 
revealed 69 (34.5%; 95% CI: 28.3%–41.3%) 
participants infected with at least one of the species of 
intestinal protozoon detected: Dientamoeba fragilis, 
Blastocystis sp., Giardia lamblia, Entamoeba coli, and 
Iodamoeba butschlii (Table 2). Helminth infection was 
not detected. Blastocystis sp. was the most commonly 
detected protozoon (31.5%; 95% CI: 25.5–38.2%). 
Dientamoeba fragilis was detected in ten (5%; 95% CI: 
2.7%–9.0%) and two (1%; 95% CI: 0.3%–3.0%) 
subjects by modified iron-hematoxylin staining and 
culture methods, respectively; while no D. fragilis 
infection was found by direct microscopy or formalin-
ether concentration methods (Table 2). 
 
Molecular analysis 
The PCR assays detected D. fragilis in 12 (6%; 95% 
CI: 3.5%–10.2%) and 27 (13.5%; 95% CI: 9.4%–
18.9%) subjects with SSU rRNA and 5.8S rRNA gene 
amplification, respectively (Table 2). Dientamoeba 
fragilis was diagnosed in 14 (13.9%; 95% CI: 8.4%–
21.9%) females and 13 (13.1%; 95% CI: 7.8%–21.2%) 
males. The mean age of D. fragilis-positive patients was 
31.7 years (SD = 19.8), ranging from one to 66 years 
(Table 1). The highest prevalence of D. fragilis 
infection (30%; 95% CI: 10.8%–60.3%) was found in 
participants 60-79 years of age (Figure 1). D. fragilis-
positive patients had been referred for clinical 
symptoms associated with D. fragilis (44.4%; 95% CI: 
27.6%–62.7%), for routine medical examination 
(51.9%; 95% CI: 34.0%–69.3%), and for non-
gastrointestinal disorders (3.7%; 95% CI: 0.7%–18.3%) 
(Table 1). Gastrointestinal complaints were diarrhea 
(18.5%, 5/27), anorexia (7.4%, 2/27), abdominal pain 
(29.6%, 8/27), flatulence (14.8%, 4/27), cramping 
(29.6%, 8/27), nausea (14.8%, 4/27), and vomiting 
(3.7%, 1/27) (Table 1). Chi-square analysis have 
revealed no relationship among D. fragilis infection and 
gender, age, reason for referral, or clinical symptoms 
The age distribution of D. fragilis-positive individuals 
compared to participating individuals is shown in 
Figure 1. 
Microscopic examination and PCR showed 79 
(39.0%; 95% CI: 32.5–45.9%) patients with intestinal 
protozoa. Single parasite infections were observed in 60 
(30%; 95% CI: 24.1–36.7%) cases. Nineteen patients 
(9.5%; 95% CI: 6.2–14.4%) had mixed parasite 
infections, with 15 (7.5%; 95% CI: 4.6–12.0%) infected 
with two, and four (2%; 95% CI: 0.8–5.0%) infected 
with three, parasites (Table 3). Among the 27 D. 
fragilis-infected patients, 14 (51.9%; 95% CI: 34.0–
69.3%) were co-infected with other intestinal protozoa. 
Ten showed double infection with Blastocystis. In four, 
Table 2. Number positive and prevalence (%) of intestinal parasites in participants referred to the clinical laboratory of Milad Hospital, 
Tehran, from March to July 2011. 
Parasite species 
Direct 
microscopy 
Formalin-ether 
concentration 
Culture 
Iron-
hematoxylin 
Dientamoeba PCR Total 
infection 
95% CIa 
of total 5.8S rRNA SSU rRNA 
Dientamoeba 
fragilis 
0 (0) 0 (0) 2 (1) 10 (5) 27 (13.5) 12 (6) 27 (13.5) 9.4–18.9 
Blastocystis sp. 21 (10.5) 22 (11) 58 (29) ND ND ND 63 (31.5) 25.5–38.2 
Giardia lamblia 2 (1) 2 (1) 0 (0) ND ND ND 2 (1) 0.3–3.6 
Entamoeba coli 4 (2) 6 (3) 4 (2) ND ND ND 7 (3.5) 1.7–7.0 
Iodamoeba butschlii 3 (1.5) 1 (0.5) 1 (0.5) ND ND ND 3 (1.5) 0.5–4.3 
Total 26 (13) 29 (14.5) 58 (29) 10 (5) 27 (13.5) 12 (6) 78 (39) 32.5–45.9 
a CI, Confidence Intervals; ND, not done; Infection percentages do not total 100% as some participants had multiple infections. 
Figure 1. Age distribution of D. fragilis-infected patients. 
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triple infection was observed: Blastocystis and G. 
lamblia in one, Blastocystis plus E. coli in two, and 
Blastocystis and I. butschlii in one (Table 3). 
Sequence analysis of SSU rRNA gene amplicons 
confirmed the D. fragilis infections. The sequences 
were aligned with the published sequences in GenBank 
using DNASIS MAX v.3.0; (Hitachi, Yokohama, 
Japan). The three sequences showed 100% homology 
without variation and were submitted to 
DDBJ/EMBL/GenBank databases under accession nos. 
AB692771–AB692773. The sequences showed a 98% 
identity with that of the D. fragilis genotype 1 accession 
no. AY730405.1 (Figure 2), with a single substitution 
of a cytosine with a thymine at position 305 and an extra 
guanine in nucleotide position 239 of the first 
nucleotide of AY7304050.1. 
 
Discussion 
Gastrointestinal parasitic infections caused by 
helminths and protozoans are common worldwide and 
occur in most parts of Iran. Factors including method of 
sample fixation and examination may bias the diagnosis 
of D. fragilis and other protozoans in stool samples 
[32]. Identification and differentiation of these parasites 
by common techniques such as direct smear and 
formalin-ether concentration has been reported to lack 
accuracy and to be laborious and time consuming 
compared to molecular assays [17,27,28,33].  
In this study we found D. fragilis infections in 
~13% of individuals referred to Milad Hospital in 
Tehran, with no correlation to gender, age, clinical 
symptoms, or reason for referral. Little information 
with respect to D. fragilis in Iran is available, and this 
is the first report of molecular diagnosis in the area. The 
obtained prevalence agreed with the reported 
prevalence of 0.4% to 71% worldwide, in which 
observed variations are primarily dependent on 
diagnostic method, the studied population, and the 
geographic region [2,12]. The reported prevalence of D. 
fragilis in Iran varies from 0.5% [21,34] by direct 
microscopy to 2%-13.2% by iron-hematoxylin staining 
or trichrome staining in patients with intestinal 
symptoms [20,22,23]. Ghazanchaei et al. [20] and 
Sarafraz et al. [22] used nested-PCR to confirm D. 
fragilis identified by permanent staining (2% and 2.4%, 
respectively).  
The impact of diagnostic methods on the reported 
prevalence of D. fragilis was clearly seen in our study. 
Although three stool samples from each individual were 
collected at different times to increase the probability of 
detecting D. fragilis and other protozoa [8,27], D. 
fragilis was not detected by direct smear or formalin-
ether concentration methods, similar to previous studies 
[22,35,36]. Two D. fragilis-infected subjects (1%) were 
revealed by the culture method. It may be that the D. 
fragilis present were dead, or there may have been an 
over-growth of other protozoa in the stool samples that 
prevented D. fragilis replication [19]. The prevalence of 
D. fragilis was 5% with iron-hematoxylin staining. 
Table 3. Number of single and multiple infections in participants referred to the clinical laboratory of Milad Hospital Tehran, from March to 
July 2011. 
 Single and multiple infections 
Parasite species 1 2 3 Total 
Dientamoeba fragilis (Df) 13 10 (Df+B)a 4 (Df+B+Gl/Ec/Ib)b 27 
Blastocystis sp. (B) 44 15 (B+Df/Ec/Ib)c 4 (B+Df+Gl/Ec/Ib) 63 
Giardia lamblia (Gl) 1 0 1 (Gl+Df+B)d 2 
Entamoeba coli (Ec) 2 3 (Ec+B) 2 (Ec+Df+B) 7 
Iodamoeba butschlii (Ib) 0 2 (Ib+B) 1 (Ib+Df+B) 3 
Number of infected patients 60 15 4 79 
a double infection of Dientamoeba with Blastocystis; b triple infection of Dientamoeba and Blastocystis with Giardia or E. coli or Iodamoeba; c double infection 
of Blastocystis with Dientamoeba or E. coli or Iodamoeba; d triple infection of Giardia, Dientamoeba and Blastocystis. 
Figure 2. Phylogenetic tree of D. fragilis genotypes constructed 
by neighbor-joining analysis, based on small subunit ribosomal 
DNA (SSU rDNA) sequences retrieved from this study 
(AB692771–3) compared with D. fragilis genotype 1 
(AY730405.1), D. fragilis genotype 2 (U37461.1), and 
Tritrichomonas foetus (M81842.1) from Genbank. Bootstrap 
values obtained from 1000 replicates are indicated on branches 
in percentage. The length of the scale bar is equivalent to a 
sequence diﬀerence of 1%. The evolutionary distances were 
computed using the Kimura 2-parameter method and are 
expressed as the number of base substitutions per site. There 
were 805 positions in the final dataset. Evolutionary analyses 
were conducted in MEGA7. 
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Grendon et al. [32] suggested that accurate and reliable 
detection of D. fragilis requires permanently stained 
preparations of fixed or fresh unpreserved stool 
specimens. However, the accuracy of this technique is 
low, as the trophozoites of D. fragilis can be easily 
overlooked due to pale staining of their nuclei, which 
may resemble those of Entamoeba spp. We used 
ethanol-preserved stool samples for PCR to prevent 
DNA fragmentation [17,28]. Prevalence varied from 
6% when targeting the SSU (18S) rRNA gene to 13.5% 
with the 5.8S rRNA gene, likely reflecting the different 
size of amplicons of the 5.8S rRNA (98 bp) and the SSU 
rRNA (887 bp) genes. Verweij et al. [28] indicated that 
the amplification of large fragments can reduce the 
sensitivity of PCR for detecting D. fragilis directly from 
stool specimens.  
In addition to conflicting reports of D. fragilis 
worldwide prevalence, the influence of gender and age 
on vulnerability to infection is unclear. Our data 
showed no significant differences in D. fragilis 
infection associated with gender or age. Nevertheless, 
the highest rate of D. fragilis (30%) was detected in 
participants 60-79 years. These results may be related 
to the limited study population, particularly of older 
participants, or might reflect a correlation of age with 
D. fragilis infection. A more comprehensive study with 
a broad age distribution is needed to resolve this issue. 
These limitations aside, this finding is similar to studies 
showing trends of higher infection rates in adults 
[9,14,37] and in contrast to some reports suggesting that 
children are common D. fragilis carriers [9,38-40]. 
Other studies have shown no influence of gender or age 
on rates of D. fragilis infection [10,27]. As in most 
gastrointestinal infections, direct exposure to the 
parasite may play a crucial role. Therefore, it is 
probable that infection by D. fragilis is related to poor 
hygiene regardless of gender or age.  
We found high overall prevalence of intestinal 
parasites (39%), including D. fragilis, Blastocystis sp., 
G. lamblia, E. coli, and I. butschlii and their co-
infections. The most frequently detected parasite was 
Blastocystis (31.5%) followed by D. fragilis (13.5%). 
The majority of D. fragilis-positive individuals showed 
co-infection with other parasites, most frequently 
Blastocystis. Co-infection of D. fragilis with other 
enteric protozoa, especially Blastocystis, has been 
widely reported [10,26,41] and could support the 
hypothesis of direct transmission of D. fragilis through 
the fecal-oral route [2,6,19,42]. Neither ova nor larvae 
of helminths were observed in the examined stool 
samples using the formalin-ether method, reflecting the 
decreasing incidence and prevalence of intestinal 
helminth infections in Iran during past two decades 
[43].  
The presented data showed no significant 
relationship between infection with D. fragilis and 
clinical symptoms or reason for referral. Many studies 
have shown correlation of infection with D. fragilis and 
clinical symptoms [3,8,9,13,39], while others report no 
relationship between symptomatic infection and this 
parasite [44-46]. This disparity is not surprising, as 
manifestations ranging from subclinical to severe 
gastrointestinal symptoms is typically observed in 
parasitic enteropathogen infections. This phenomenon 
is suggested to be related to genetic diversity in D. 
fragilis, resulting in a heterogeneous species 
[2,4,8,47,48].  
Currently, two genotypes are described for D. 
fragilis, with genotype 1 being the most common [48]. 
The investigation of genetic variation in D. fragilis SSU 
rRNA with respect to geographic area has shown that 
SSU rRNA gene variation is not sufficient to be used as 
an epidemiological marker [4,47,48]. The SSU rRNA 
gene sequencing analysis of three D. fragilis isolates 
were similar and revealed 98% identity between our 
isolates and two corresponding published reference 
sequences for D. fragilis (accession nos. AY730405.1 
and FJ649228.1). These results indicated low level of 
polymorphism, in agreement with recent studies 
[47,49].  
 
Conclusions 
This study demonstrated high prevalence of D. 
fragilis in Tehran via laboratory fecal analysis. Hence, 
clinical diagnostic laboratories should include 
screening for this parasite in routine stool examination. 
The PCR assay targeting the 5.8S rRNA gene detected 
a significantly greater number of D. fragilis-infected 
patients than did other analyses and is recommended as 
an effective tool for the accurate diagnosis of D. fragilis 
that should be employed in combination with 
microscopic methods to obtain a complete assessment 
of intestinal parasite infection. The use of these 
methods will prevent a high number of undiagnosed 
infections. Therefore, further studies applying this 
method to obtain accurate data on the prevalence of 
infection in specific age groups, symptomatic and 
asymptomatic individuals, other animals, and possibly 
a population-wide study, are required to ascertain 
epidemiology, pathogenicity, and transmission routes, 
as well as to identify reservoirs of D. fragilis.  
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